This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility
by Zacks Equity Research
Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.
Here's Why You Should Buy Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.
LabCorp (LH) to Expand Diagnostics Services With New Deal
by Zacks Equity Research
LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.
QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay
by Zacks Equity Research
QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.
Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG
by Zacks Equity Research
Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
International expansion and the strong prospects of the CSS segment bode well for Integra (IART).
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
by Zacks Equity Research
Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), led by progress in the Food Safety business and recent product launches.
Medtronic (MDT) to Launch Academic R&D Grants With New Pact
by Zacks Equity Research
Medtronic's (MDT) partnership will enable teachers to improve their skill set, boosting student opportunities to pursue STEM careers in corporate America.
Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails
by Zacks Equity Research
Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.
Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter
by Zacks Equity Research
Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.
Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump
by Zacks Equity Research
Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.
Are Medical Stocks Lagging Align Technology (ALGN) This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring
by Zacks Equity Research
DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Reasons to Retain Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024
by Zacks Equity Research
HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Align (ALGN) Gains From Growing Invisalign Volume, Innovation
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.